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Conclusions: These data suggest: (1) persistent ‘minor’ pN2-disease 
following induction chemotherapy does not always exclude favourable 
outcome after surgery; (2) serial FDG-PET is able to select surgical 
candidates amongst patients with persistent ‘minor’ pN2-disease or 
with mediastinal clearance; (3) persistent ‘major’ pN2-disease has a 
poor prognosis and should not be considered for surgery.
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Prognostic significance of AJCC T2 descriptor-visceral pleura 
invasion, hilar atelectasis or obstructive pneumonitis for stage IB 
non-small-cell lung cancer (NSCLC) is dependent on tumor size
Ou, Sai-Hong I.1 Zell, Jason A.1 Ziogas, Argyrios2 Anton-Culver, Hoda2 
1 Chao Family Comprehensive Cancer Center, Orange, CA, USA 2 
Genetic Epidemiology Research Institute, Irvine, CA, USA 
Background: The T2 descriptor in the AJCC staging for non-small-
cell lung cancer (NSCLC) contains several non-size based criteria in 
addition to the criterion of tumor size greater than 3 cm. It remains un-
known if there are survival differences between patients whose tumors 
were staged according to these non-size based criteria when compared 
to patients whose tumors were staged according to tumor size.
Methods: We analyzed 10,545 stage IB NSCLC patients from the Cali-
fornia Cancer Registry (CCR) from 1989 to 2003. These patients were 
staged as IB disease according to three non-overlapping main criteria: 
1) tumor size [T2S]; 2) visceral pleura invasion, hilar atelectasis or 
obstructive pneumonitis [T2P]; 3) main bronchus involvement ≥ 2 cm 
from the carina [T2C]. Univariate survival analyses were conducted 
using the Kaplan-Meier method. Multivariate survival analyses were 
performed using Cox proportional hazards ratios.
Results: 5385 (51.1%) IB patients were staged according to tumor size 
[T2S], 4557 (43.2%) patients were staged by visceral pleura invasion, 
hilar atelectasis or obstructive pneumonitis [T2P] and 603 (5.7%) 
patients were staged by main bronchus involvement ≥ 2 cm from the 
carina [T2C]. 35.7% of the IB patients due to visceral pleura invasion, 
hilar atelectasis or obstructive pneumonitis [T2P] and 29.7% of the pa-
tients due to main bronchus involvement ≥ 2 cm from the carina [T2C] 
had tumors 3 cm or smaller. There was statistical significant difference 
in the 5-year survivorship and median overall survival (OS) among the 
3 types of stage IB NSCLC patients: (T2C: 38.6% and 39 months; T2P: 
38.0% and 38 months; T2C: 40.3% and 39 months; P = 0.0031). The 
5-year survival and median OS of these IB patients with tumor 3 cm or 
smaller were 53.3% and 67 months for T2P and 52.6% and 73 months 
for T2C respectively, similar to the 53.2% 5-year survival and 67 
months of median OS for stage IA patients. Cox proportional hazards 
model revealed that T2P > 3 cm is a poor prognostic factor (vs. T2S, 
Hazard Ratio [HR] = 1.13, 95% Confidence Interval (CI) = 1.06-1.20) 
while T2P ≤ 3 cm was a favorable prognostic factor (vs. T2S, HR = 
0.87, 95% CI = 0.80-0.95). T2C > 3 cm (vs. T2S, HR = 0.98, 95% CI = 
0.84-1.13) and T2C ≤ 3 cm (vs. T2S, HR = 0.86, 95% CI = 0.69-1.08) 
were not independent poor prognostic factors.
Conclusions: Non-size based T2 descriptors-visceral pleura inva-
sion, hilar atelectasis or obstructive pneumonitis are poor independent 
prognostic factors when the tumor size was greater than 3 cm. Stage IB 
NSCLC patients staged by non-size based criteria T2 descriptors whose 
tumors were 3 cm or smaller had survival similar to stage IA NSCLC 
patients. Future proposed changes to the AJCC T2 descriptor, the 
non-size based criteria should be linked to size criteria rather than as 
independent criteria. The prognostic signiﬁcance of the T2C criterion 
requries further studies.
Cox proportional hazards model showing prognostic signiﬁcance of 
various AJCC T2 descrpitors.
T2 descriptor
Number of 
patients
Hazard ratio
95% Conﬁdence 
interval
P-value
T2S 5385 1.00   
T2P > 3 cm 2960 1.127 (1.056-1.202) 0.0003
T2P ≤ 3 cm 1597 0.869 (0.796-0.948) 0.0016
T2C > 3 cm 424 0.975 (0.841-1.130) 0.7343
T2C ≤ 3 cm 179 0.863 (0.693-1.075) 0.1895
 
Adjustment included: age at diagnosis, gender, race, socioeconomic 
status, marital status, histology, histologic grade, tumor lobar location, 
surgical treatment, chemotherapy and radiation.
T2S-T2 descriptor: by size only
T2P-T2 descriptor: visceral pleura invasion, hilar atelectasis or obstruc-
tive pneumonitis
T2C-T2 descriptor: main bronchus involvement ≥ 2 cm from carina
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Preliminary experience with mediastinal staging of patients with 
non-small cell lung cancer using endobronchial ultrasound (EBUS/
TBNA)
Jørgensen, Ole D.; Ømark, Henrik; Eckardt Jens; Olsen, Karen E. 
Odense University Hospital, Odense, Denmark
Background: Treatment and prognosis of patients with non-small 
cell lung cancer depend on the stage of the disease at the time of the 
diagnosis. Mediastinoscopy has been the golden standard for staging of 
the mediastinum for many years, and it has been proven that the false 
negative rate of N2-disease by this procedure is near 20% or more. The 
consequence of this is often a futile thoracotomy without beneﬁt for the 
patient. 
We would like to report the results of our preliminary experience with 
EBUS/TBNA for staging of the mediastinum. 
Methods: A total of 152 consecutive patients were examined by 
EBUS/TBNA during the ﬁrst year (2006) the method was used in our 
department. The indication was mediastinal staging in 82 patients 
(53.9%). The remaining 70 patients were examined because of an 
undiagnosed mediastinal mass, follow-up after resection of NSCLC, or 
restaging after chemotherapy. The 3 examiners had no previous experi-
ence with endoscopic ultrasound, but were trained for a period of 2 
days in another institution with experience in the method. 
The examinations of the 82 patients were carried out in general an-
aesthesia with a linear scanner (BF-UC160F, Olympus). Cytological 
samples were taken by 22G needle aspiration (NA-201SX-4022, Olym-
pus) from all lymph node stations visualized. Patients positive for N2 
or N3-disease (n=32) by EBUS/TBNA were not examined further, but 
referred to oncological treatment. Patients without N2 or N3-disease 
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(n=50) detected by EBUS/TBNA were examined by a supplementary 
mediastinoscopy (n=34), unless the examiner was conﬁdent that the 
risk of N2-disease was small, as judged from the ﬁndings on the CT-
scan and the endoscopic ultrasound image (n=16).
Results: N2 or N3-disease was found in 40 patients (48.8%) by 
EBUS/TBNA, mediastinoscopy or surgery. EBUS was false negative 
in 8 patients (9.8%) of whom 4 had N2-disease in the aortopulmonary 
window - outside the range of EBUS/TBNA. No complications to the 
staging procedures occurred.
Conclusion: Our preliminary experience with staging of the mediasti-
num with EBUS/TBNA suggests that the method is safe and accurate 
and at least as good as mediastinoscopy. Furthermore the method is less 
invasive and allows easier restaging. The method can easily be learned 
- even by thoracic surgeons without previous experience with endo-
scopic ultrasound.
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The combination of total tumor volume, number of positive lymph 
node stations on PET, gender, performance status and radiation 
dose is the best predictor for survival in patients with inoperable 
NSCLC, stage I-IIIB, treated with (chemo)radiation
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Hochstenbag, Monique2 Geraedts, Wiel3 Pitz, Cordula4 Simons, Jean5 
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Sint Jans Hospital, Weert, The Netherlands 6 Atrium Medical Center, 
Heerlen, The Netherlands 7 Siemens Medical Solutions, Philadelphia, 
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Background: Accurately predicting survival of NSCLC patients is 
important for treatment decision making. However, it is widely recog-
nized that the UICC (TNM) staging system has its shortcomings when 
used for the risk stratiﬁcation of inoperable NSCLC patients treated 
with (chemo)radiotherapy. Factors that are lacking and may be impor-
tant for the outcome after (chemo)radiation include size of the tumor 
(which is not taken into account as a continuous variable), gender, per-
formance status and radiation dose. In addition, the number of positive 
lymph nodes is not taken into account, whereas it is of prognostic value 
for surgical patients. As it is possible to assess the mediastinal lymph 
nodes with FDG-PET scans, we hypothesized that also for non-surgical 
patients, this would affect survival. 
Purpose: To investigate the prognostic value of tumor volume (as-
sessed by CT), the number of positive lymph node stations (assessed 
by PET), gender, performance status and equivalent radiation dose 
corrected for time (EQD
2,T
) for overall survival, and compare this 
with UICC stage in patients with inoperable NSCLC treated with 
(chemo)radiotherapy.
Methods: Clinical data from 270 inoperable NSCLC patients, UICC 
stage I-IIIB, treated at MAASTRO clinic with (chemo)radiotherapy, 
was collected retrospectively. Diagnostic imaging was performed either 
with an integrated PET-CT or with CT-scan and PET-scan separately. 
Overall survival was calculated from the start of radiotherapy treat-
ment. A logarithmic transformation was applied to obtain more sym-
metrically distributed data for the tumor volume. The Kaplan-Meier 
method as well as Cox regression were used to analyze the data. The 
likelihood ratio test (LR test) was applied to compare the performance 
of the models. The resulting p-values were reported. In addition, 
Akaike’s information criterion (AIC) was calculated. The AIC takes 
into account how well the model ﬁts the data as well as the complexity 
of a model, e.g. the number of estimated variables, thereby reducing the 
risk of overﬁtting. The preferred model is the one with the lowest AIC 
value. To assess the relative merits of a model the difference is inter-
preted as follows: 4-7 indicates less support, ≥10 indicates essentially 
no support for a model. 
Results: Univariate analysis showed that the number of positive lymph 
node stations, N-stage as well as T-stage were signiﬁcantly associated 
with survival. However, in the ﬁnal multivariate Cox regression, N-
stage was no longer signiﬁcant. A comparison was made between three 
multivariate models each consisting of gender, WHO-performance sta-
tus, EQD
2,T
 and only one of the following combinations: 1) total tumor 
volume and number of positive lymph node stations, 2) T-stage and N-
stage, 3) UICC overall stage. The p-values of the LR test were <0.001, 
0.004 and 0.99 respectively. The AIC of the models was 1965.8, 1989.9 
and 2001.2 respectively. It was therefore concluded that model 1 was 
the most informative for prediction of overall survival. 
Conclusions: The combination of total tumor volume, number of posi-
tive lymph node stations, gender, performance status and equivalent 
radiation dose corrected for time (EQD
2,T
) is the best predictor for sur-
vival in NSCLC patients, stage I-IIIB, treated with (chemo)radiation. 
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Has primary tumour standardized maximum uptake value 
(SUV max) measured on fluorodeoxyglucose positron emission 
tomography (FDG-PET) a prognostic value for survival in non-
small cell lung cancer (NSCLC) ? A systematic review and meta-
analysis (MA) by the European Lung Cancer Working Party for 
the IASLC Staging Project
Paesmans, Marianne1 Dusart, Michelle1 Berghmans, Thierry1 Hossein-
Foucher, Claude2 Castaigne, Catherine3 Scherpereel, Arnaud4 Mascaux, 
Celine5 Moreau, Michel1 Roelandts, Martine1 Alard, Stéphane3 Meert, 
Anne-Pascale1 Laﬁtte, Jean-Jacques4 Patz, Ned6 Sculier, Jean-Paul1 
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Background: FDG-PET is an imaging tool for assessing cTNM in 
NSCLC. Further, SUV max, measured on the primary tumor, has been 
studied as a potential prognostic factor for survival in several studies. 
However, the sample sizes are limited leading to an indication for con-
ducting a MA to improve the precision in estimating its effect.
Methods: We performed a systematic literature search and we assessed 
the methodology of each eligible study (using a non validated quan-
titative scale with 44 points for the clinical data and 40 points for the 
FDG-PET data designed for the purpose of the review). For each publi-
cation, we extracted an estimate of the hazard ratio (HR) for comparing 
patients with a low or high SUV and aggregated the individual HRs 
into a combined HR, using a random-effects model.
Results: We found 12 eligible studies, published between 1998 and 
2006 and dedicated to NSCLC only. Most of them included patients 
with stages I to III/IV and used a SUV assessment corrected for weight. 
Numbers of patients ranged from 19 to 162 (total: 1127); 9 studies 
identiﬁed a high SUV max as a poor prognostic factor for survival 
